The Checkup by Singlecare

MAY 5, 2024

Food and Drug Administration ( FDA ) to treat human immunodeficiency virus type 1 (HIV-1) infections. Biktarvy is recommended as an initial treatment option for people starting HIV-1 therapy. There are other FDA-approved options available to treat HIV-1 infections that do not improve with Biktarvy.

Immunization 98

Immunization People Management FDA Dosage 98

The Checkup by Singlecare

DECEMBER 10, 2024

While an effective treatment for some people, Breo Ellipta may not be the best option for all people managing persistent asthma or COPD symptoms. Not all people with asthma will require a maintenance inhaler or a combination maintenance inhaler , and not all people with COPD will require a combination maintenance inhaler.

Generic Medicine 88

Generic Medicine People Management FDA Dosage 88

The Checkup by Singlecare

JANUARY 10, 2025

For example, although its approved by the Food and Drug Administration (FDA) to treat seizures and nerve pain, it may be prescribed off-label for chronic muscle pain (fibromyalgia), generalized anxiety disorder, and alcohol withdrawal, among other uses. Therefore, the medications drawbacks may outweigh the potential benefits for some people.

Dosage 52

Dosage Insurance Labelling Insurance Coverage 52

The Checkup by Singlecare

JULY 3, 2024

Food and Drug Administration (FDA) to treat mental health conditions like obsessive-compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD). The medication is approved by the U.S.

Adverse Reactions 92

Adverse Reactions Dosage People Management Communication 92